title: Perspectives of differentiation therapies of acute myeloid leukemia: the search for the molecular basis of patients' variable responses to 1,25-dihydroxyvitamin d and vitamin d analogs.
abstract: The concept of differentiation therapy of cancer is ~40 years old. Despite many encouraging results obtained in laboratories, both in vitro and in vivo studies, the only really successful clinical application of differentiation therapy was all-trans-retinoic acid (ATRA)-based therapy of acute promyelocytic leukemia (APL). ATRA, which induces granulocytic differentiation of APL leukemic blasts, has revolutionized the therapy of this disease by converting it from a fatal to a curable one. However, ATRA does not work for other acute myeloid leukemias (AMLs). Since 1,25-dihydroxyvitamin D3 (1,25D) is capable of inducing monocytic differentiation of leukemic cells, the idea of treating other AMLs with vitamin D analogs (VDAs) was widely accepted. Also, some types of solid cancers responded to in vitro applied VDAs, and hence it was postulated that VDAs can be used in many clinical applications. However, early clinical trials in which cancer patients were treated either with 1,25D or with VDAs, did not lead to conclusive results. In order to search for a molecular basis of such unpredictable responses of AML patients toward VDAs, we performed ex vivo experiments using patient's blast cells. Experiments were also performed using 1,25D-responsive and 1,25D-non-responsive cell lines, to study their mechanisms of resistance toward 1,25D-induced differentiation. We found that one of the possible reasons might be due to a very low expression level of vitamin D receptor (VDR) mRNA in resistant cells, which can be increased by exposing the cells to ATRA. Our considerations concerning the molecular mechanism behind the low VDR expression and its regulation by ATRA are reported in this paper.
authors.affiliation: Faculty of Biotechnology, University of Wroclaw , Wroclaw , Poland.
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Marchwicka
authors.affiliation: Laboratory of Molecular and Cellular Immunology, Institute of Immunology and Experimental Therapy, Polish Academy of Science , Wroclaw , Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Cebrat
authors.affiliation: Faculty of Biotechnology, University of Wroclaw , Wroclaw , Poland.
authors.forename: Preetha
authors.initials: P
authors.lastname: Sampath
authors.affiliation: Laboratory of Molecular and Cellular Immunology, Institute of Immunology and Experimental Therapy, Polish Academy of Science , Wroclaw , Poland.
authors.forename: Lukasz
authors.initials: L
authors.lastname: Snieżewski
authors.affiliation: Faculty of Biotechnology, University of Wroclaw , Wroclaw , Poland.
authors.forename: Ewa
authors.initials: E
authors.lastname: Marcinkowska
keywords: 1,25-dihydroxyvitamin D3; all-trans-retinoic acid; cancer; differentiation; exon; gene; leukemia; vitamin D receptor